Channel therapeutics announces positive efficacy data for a depot formulation of a nav1.7 inhibitor in a preclinical in vivo nerve block model

Freehold, n.j., dec. 18, 2024 (globe newswire) -- channel therapeutics corporation, (“channel” or the “company”), (nyse american: chro), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it achieved its endpoints in two pre-clinical in vivo models of the company's nerve block formulations for acute pain, showing material improvement over the existing standard of care, bupivacaine, in both efficacy and duration.
CHRO Ratings Summary
CHRO Quant Ranking